COMPANY PROFILE

Maze Therapeutics

Translating genetic insights into new medicines

South San Francisco, United StatesFounded 2018Biotech & Life Sciences

Valuation $1.81B Market cap · 2026

Revenue $168M Latest reported FY

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biotechnology company that develops precision medicines for common diseases with large unmet medical needs. The company was founded in 2018 and harnesses advances in human genetics to identify naturally occurring protective genetic variants and design small-molecule medicines that imitate their effects. Its lead program MZE829 targets APOL1-mediated kidney disease, a condition associated with high-risk APOL1 gene variants. A second program MZE782 is in development for chronic kidney disease and phenylketonuria, an inherited metabolic disorder. The company's drug discovery platform Compass uses variant functionalization to link genetic insights with therapeutic targets, and Maze operates across research, preclinical development, and clinical trials. As a clinical-stage company, Maze has not yet commercialized products, and its business model centers on developing and ultimately commercializing its own precision medicines.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2018
Headquarters: South San Francisco, United States
Listing: IPO 2025
Employees: 159
Open positions: 10
Dealroom signal: 81.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITYOther financing	Apr 2026	$150M	—	Driehaus Capital Management · T. Rowe Price · Frazier Life Sciences · Farallon Capital Management	↗
POST IPO DEBTDebt	Feb 2026	$0	—	Hercules Capital	↗

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Maze Therapeutics website traffic

Latest recorded traffic for Maze Therapeutics is 15K monthly website visits, up 0% over the last three months. Maze Therapeutics's team grew 9.7% over the past year.

Latest monthly visits15K 3-month web change0% 1-year team growth+9.7%

Monthly website visitsMay 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Manager, Chemical Development New South San Francisco, CASan Francisco, California, United States, Northern America, Americas · Other · Aug 28, 2026 Senior Project Manager, Clinical Operations New South San Francisco, CASan Francisco, California, United States, Northern America, Americas · Project Management · Aug 14, 2026 Trial Master File Sr. Manager, Clinical Operations New South San Francisco, CASan Francisco, California, United States, Northern America, Americas · Other · Aug 14, 2026 Oversight Director, Clinical Operations New South San Francisco, CASan Francisco, California, United States, Northern America, Americas · Other · Aug 5, 2026 Director, Clinical Business Operations New South San Francisco, CASan Francisco, California, United States, Northern America, Americas · Business Development · Aug 5, 2026 Director, Clinical Operations New South San Francisco, CASan Francisco, California, United States, Northern America, Americas · Other · Aug 5, 2026 Director, R&D FP&ASouth San Francisco, CA · Other · Jul 25, 2026 Regulatory Project Manager/Senior Manager New South San Francisco, CASan Francisco, California, United States, Northern America, Americas · Project Management · Jul 22, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
AUAutoGenomicsPioneer in developing the automated microarray based multiplexing molecular diagnostic platforms	Vista, United States	Operational	43	$29M	$48M
BIBillionToOneThe only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level	Menlo Park, United States	Operational
PRProstaGeneBiotechnology start up company that is developing technology based on patents	United States	Acquired
GGGene by GeneSpecializing in DNA-based ancestry & genealogy as Family Tree DNA	Houston, United States	Operational
GEGENEWIZLeading global genomics service company	Plainfield, United States	Low Activity
ANAnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market	Dongcheng District, China	Operational
PTProQR TherapeuticsDevelops RNA therapies to potentially transform the lives of patients suffering from genetic rare diseases	Leiden, Netherlands	Operational
BIBiogeneraThe unique and patented biotechnology platform to generate personalized DNA drugs for incurable diseases	Ozzano dell'Emilia, Italy	Operational